MacroGenics
Update in progressMGNX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
MacroGenics is a clinical‑stage biopharmaceutical company developing antibody‑based cancer therapies in the United States. Its pipeline includes lorigerlimab, a bispecific DART that targets PD‑1 and CTLA‑4 for metastatic castration‑resistant prostate cancer and platinum‑resistant ovarian and clear cell gynecologic cancers; MGC026, an anti–B7‑H3 ADC with a TOP1 inhibitor payload; MGC028, an anti‑ADAM9 ADC with a TOP1i payload; and MGC030, an undisclosed‑antigen ADC in preclinical, plus T‑cell engager programs. Collaborations: TerSera, Incyte, Gilead. Founded 2000; based in Rockville, MD.
Company score
- Sentiment
- -0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.68
- Governance
- -0.30
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.27
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!